- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
176 result(s) found for: Sodium MRI.
Displaying page 9 of 9.
EudraCT Number: 2013-002403-34 | Sponsor Protocol Number: 009175QM | Start Date*: 2014-04-15 |
Sponsor Name:Queen Mary, University of London | ||
Full Title: A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer. | ||
Medical condition: Estrogen receptor-positive advanced or metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) ES (Completed) HU (Completed) FR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-004277-26 | Sponsor Protocol Number: GS-US-205-0110 | Start Date*: 2008-04-29 | |||||||||||
Sponsor Name:Gilead Sciences Inc | |||||||||||||
Full Title: An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebuliser Solution (AZLI) versus Tobramycin Nebuliser Solution (TNS) in an Int... | |||||||||||||
Medical condition: Adult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) ES (Completed) GB (Completed) IE (Completed) DK (Completed) DE (Completed) NL (Completed) IT (Completed) PT (Completed) AT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001515-31 | Sponsor Protocol Number: NEOMERO-1 | Start Date*: 2011-08-25 | |||||||||||
Sponsor Name:FONDAZIONE PENTA ONLUS | |||||||||||||
Full Title: EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL | |||||||||||||
Medical condition: late onset sepsis in the neonate and infant up to 90 days of age | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001429-26 | Sponsor Protocol Number: ZP1848-17127 | Start Date*: 2019-05-08 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS) | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) DK (Completed) PL (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001772-28 | Sponsor Protocol Number: PAC203 | Start Date*: 2017-10-23 | ||||||||||||||||||||||||||
Sponsor Name:CTI BioPharma Corp. | ||||||||||||||||||||||||||||
Full Title: Phase 3 Study (PACIFICA): A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essent... | ||||||||||||||||||||||||||||
Medical condition: Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/µL), Post polycythaemia vera myelofibrosis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) SE (Completed) ES (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003177-58 | Sponsor Protocol Number: SPIOMET4HEALTH | Start Date*: 2022-05-12 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu (FSJD) | |||||||||||||
Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO... | |||||||||||||
Medical condition: Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000111-69 | Sponsor Protocol Number: PAC303 | Start Date*: 2020-08-04 | |||||||||||||||||||||
Sponsor Name:CTI BioPharma Corp. | |||||||||||||||||||||||
Full Title: PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thro... | |||||||||||||||||||||||
Medical condition: Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001521-25 | Sponsor Protocol Number: NEOMERO-2 | Start Date*: 2011-12-15 | |||||||||||
Sponsor Name:FONDAZIONE PENTA ONLUS | |||||||||||||
Full Title: Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial | |||||||||||||
Medical condition: Bacterial meningitis in children up to 90 days of age | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) NL (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002249-22 | Sponsor Protocol Number: D-V | Start Date*: 2015-07-15 |
Sponsor Name:Universitätsklinikum Ulm (AöR) | ||
Full Title: DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pert... | ||
Medical condition: Patients with HER2-positive and hormone-receptor positive metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005825-12 | Sponsor Protocol Number: PB-06-002 | Start Date*: 2009-06-04 | |||||||||||
Sponsor Name:Protalix Biotherapeutics | |||||||||||||
Full Title: Ensayo clinico de fase 3, multicéntrico, en abierto y con cambio de tratamiento para evaluar la seguridad y eficacia de Glucocerebrosidasa Humana Recombinante expresada en células vegetales (prGCD)... | |||||||||||||
Medical condition: Enfermedad de Gaucher Gaucher Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) IT (Completed) DE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000553-40 | Sponsor Protocol Number: CNIS793E12201 | Start Date*: 2021-11-18 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer th... | ||||||||||||||||||
Medical condition: metastatic colorectal cancer (mCRC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) DE (Completed) HU (Prematurely Ended) ES (Temporarily Halted) BE (Completed) IT (Prematurely Ended) FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022382-10 | Sponsor Protocol Number: CCX114151 | Start Date*: 2011-01-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease | |||||||||||||
Medical condition: Subjects with Moderately-to-Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) CZ (Completed) SE (Prematurely Ended) NO (Completed) BE (Completed) DK (Completed) HU (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002393-27 | Sponsor Protocol Number: TL-895-201 | Start Date*: 2021-02-23 | |||||||||||
Sponsor Name:Telios Pharma, Inc. | |||||||||||||
Full Title: A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligibl... | |||||||||||||
Medical condition: Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Ongoing) HU (Completed) BE (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) HR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004372-27 | Sponsor Protocol Number: 0112 | Start Date*: 2016-05-17 | |||||||||||
Sponsor Name:Theravance Biopharma Ireland Limited | |||||||||||||
Full Title: A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infectiv... | |||||||||||||
Medical condition: Staphylococcus aureus Bacteremia Including Infective Endocarditis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) LV (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004391-39 | Sponsor Protocol Number: CTKI258A2107 | Start Date*: 2008-04-15 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) | |||||||||||||
Medical condition: advanced or metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005397-34 | Sponsor Protocol Number: Issue1 | Start Date*: 2012-02-24 | |||||||||||||||||||||
Sponsor Name:University Hospital Bristol NHS Foundation Trust | |||||||||||||||||||||||
Full Title: Xenon and cooling therapy in babies at high risk of brain injury following poor condition at birth: Randomised pilot study. (CoolXenon2 study) | |||||||||||||||||||||||
Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
